# **GSK-LSD1** dihydrochloride

Cat. No.: HY-100546A CAS No.: 2102933-95-7 Molecular Formula:  $C_{14}H_{22}Cl_2N_2$ Molecular Weight: 289.24

Target: Histone Demethylase; Monoamine Oxidase

Pathway: Epigenetics; Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO:  $\geq$  62.5 mg/mL (216.08 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.4573 mL	17.2867 mL	34.5734 mL
	5 mM	0.6915 mL	3.4573 mL	6.9147 mL
	10 mM	0.3457 mL	1.7287 mL	3.4573 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.19 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.19 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.19 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC $_{50}$ of 16 nM.	
IC <sub>50</sub> & Target	IC50: 16 nM (LSD1) <sup>[1]</sup>	
In Vitro	GSK-LSD1 shows more than 1000 fold selectivity over other closely related FAD utilizing enzymes including LSD2, and monoamine oxidases MAO-A, MAO-B $^{[1]}$ . GSK-LSD1 can inhibit KDM1A/LSD1 enzyme activity. GSK-LSD1 induces the formation of LC3-II in U2OS cells. The electronic microscopy shows the formation of autophagosome with GSK-LSD1	

treatment. GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **CUSTOMER VALIDATION**

- Signal Transduct Target Ther. 2022 Apr 13;7(1):102.
- Adv Mater. 2021 May;33(18):e2100949.
- Nat Commun. 2021 Dec 8;12(1):7142.
- Cytokine. 2022 Jan 5;151:155789.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Purich D. The Inhibitor Index A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads. ISBN 9781138739215

[2]. Wang Z, et al. Inhibition of H3K4 demethylation induces autophagy in cancer cell lines. Biochim Biophys Acta. 2017 Aug 8;1864(12):2428-2437.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA